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 2 
Abstract 14 
Vitamin D deficiency is a common occurrence globally, and particularly so in pregnancy. There is 15 
conflicting evidence regarding the role of vitamin D during pregnancy on non-skeletal health 16 
outcomes for both the mother and the neonate. The aim of this study was to investigate the 17 
associations of maternal total 25-hydroxy vitamin D (25OHD) with neonatal anthropometrics, and 18 
markers of neonatal glycaemia in the Belfast centre of the Hyperglycemia and Adverse Pregnancy 19 
Outcome (HAPO) study. Serological samples (n=1585) were obtained from pregnant women in the 20 
Royal Jubilee Maternity Hospital, Belfast, Northern Ireland between 24-32 weeks gestation as part 21 
of the HAPO study. 25OHD concentrations were measured by liquid chromatography tandem mass 22 
spectrometry (LC-MS/MS). Cord blood and neonatal anthropometric measurements were obtained 23 
within 72h of birth. Statistical analysis was performed. Following adjustment for confounders, birth 24 
weight standard deviation scores (SDS) and birth length SDS were significantly associated with 25 
maternal total 25OHD. A doubling of maternal 25OHD at 28 weeks’ gestation was associated with 26 
mean birth weight SDS and mean birth length SDS higher by 0.05 and 0.07, respectively (both, 27 
p=0.03). There were no significant associations with maternal 25OHD and other measures of 28 
neonatal anthropometrics or markers of neonatal glycaemia. In conclusion, maternal total 25OHD 29 
during pregnancy was independently associated with several neonatal anthropometric 30 
measurements; however, this association was relatively weak.  31 
3 
Introduction 32 
Vitamin D deficiency in pregnancy is a common occurrence globally(1). Adequate vitamin D intake 33 
during pregnancy is required to address the ongoing demand for calcium for fetal growth and 34 
development (2). In addition, vitamin D has been associated with a number of neonatal outcomes 35 
including neonatal birth length and weight (3),(4). Pérez-López and colleagues (3) conducted a 36 
systematic review and meta-analysis of randomised controlled trials (RCT) which examined 37 
vitamin D supplementation during pregnancy with various neonatal outcomes. They observed that 38 
neonatal birth weight and birth length were significantly greater in the vitamin D intervention 39 
groups than the placebo group. However, evidence surrounding a possible beneficial relation 40 
between vitamin D and birth weight is conflicting. Harvey and colleagues (5) carried out a 41 
comprehensive systematic review on the relationship of vitamin D with maternal and neonatal 42 
health outcomes. They observed a modest relationship between maternal 25OHD status and 43 
offspring birth weight and bone mass in observational studies(5). Observational studies which 44 
directly measured maternal serum 25OHD, reported no association of serum 25OHD with low birth 45 
weight (6). The lack of clear evidence suggests a need for larger observational and potentially, 46 
intervention trials, to further investigate this relation.  47 
It has been hypothesised that destruction of beta cells in the development of type 1 diabetes may 48 
occur before birth (7) and, if correct, then early identification of environmental determinants in utero 49 
which could affect beta cell function is of particular relevance. Preliminary reports have suggested 50 
that vitamin D deficiency is associated with decreased beta cell function (8),(9), and as neonates 51 
derive vitamin D from their mother, it is crucial to confirm or refute these findings. 52 
The aim of this study was to investigate the associations of maternal total 25-hydroxy vitamin D 53 
(25OHD) with neonatal anthropometrics and markers of neonatal glycaemia in the Hyperglycemia 54 
and Adverse Pregnancy Outcome (HAPO) study at the Belfast centre.  55 
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Subjects and methods 57 
The methods for the HAPO study have been published in detail elsewhere (10),(11). Briefly, the 58 
HAPO study was a 15-center multicultural and multinational study designed to examine the 59 
association between maternal hyperglycemia and adverse pregnancy outcomes in singleton 60 
pregnancies whose results on oral glucose tolerance testing (OGTT) were below the traditional 61 
thresholds for overt diabetes. All pregnant women at a given centre were eligible to participate 62 
unless they had one or more of the following exclusion criteria: age younger than 18 years, a plan to 63 
undergo delivery at another hospital, an uncertain date of last menstrual period and no 64 
ultrasonographic estimation between 6 and 24 weeks of gestational age, inability to complete the 65 
oral glucose-tolerance test within 32 weeks of gestation, multiple pregnancy, conception by means 66 
of gonadotropin ovulation induction or in vitro fertilization, glucose testing before recruitment or a 67 
diagnosis of diabetes during the current pregnancy, diagnosis of diabetes before the current 68 
pregnancy and requiring treatment with medication, participation in another study that could 69 
interfere with the HAPO study, infection with the human immunodeficiency virus or hepatitis B or 70 
C virus, previous participation in the HAPO study, or inability to converse in the languages used on 71 
center forms without the aid of an interpreter. 72 
Each participant underwent a standard 75g OGTT between 24-32 weeks gestation (average 28 73 
weeks), with sampling of plasma glucose fasting and at one hour and two hours. OGTT results were 74 
blinded to the clinician responsible for the care of the pregnant woman unless the fasting plasma 75 
glucose level exceeded 5.8 mmol/L or the 2-hour post-load level exceeded 11.1 mmol/L. Additional 76 
blood samples were collected concurrently for storage and future biomarker analysis. A number of 77 
standardised questionnaires were used to determine information about the mother including age at 78 
OGTT, pre-pregnancy BMI, family history of diabetes, parity and years in education. Maternal 79 
height, weight and blood pressure were measured at the OGTT. The number of cigarettes smoked 80 
during pregnancy per day and the number of alcoholic drinks taken during pregnancy per day were 81 
collected using a standardised questionnaire at the time of the OGTT. This information was used to 82 
derive smoking status (≥1 cigarette per day) and alcohol use during pregnancy (≥1 drink/per day). 83 
In addition, Belfast centre participants at their OGTT visit completed a semi-quantitative validated 84 
food-frequency questionnaire (FFQ) which was used to assess usual dietary intake (12). Mean dietary 85 
vitamin D intake was calculated from the FFQ using the nutritional software package Q-Builder 86 
(Questionnaire Design System), version 2.0 (Tinuviel Software, Anglesey, UK) which uses United 87 
Kingdom (UK) food composition tables to quantify nutrient intakes (13). Quantification of dietary 88 
intake of vitamin D was based on food sources alone, as the FFQ was not designed to ascertain the 89 
quantification of vitamin D entering the diet via food fortification or vitamin supplementation. 90 
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A random blood sample was also collected between 34 and 37 weeks’ gestation to identify woman 91 
with undiagnosed diabetes in late gestation. If the plasma glucose equalled or exceeded 8.9 nmol/L 92 
or was less than or equal to 2.5 nmol/L, the result was unblinded to the medical caregivers 93 
responsible for the pregnant woman. 94 
Cord blood specimens were collected at delivery for the analysis of serum C-peptide and plasma 95 
glucose. Outcome measures included delivery method (including any adverse outcomes such as 96 
shoulder dystocia and birth injury); birth weight, birth length, head circumference and neonatal skin 97 
fold thickness measurements. All neonatal anthropometric measurements were obtained within 72 98 
hours by trained HAPO personnel, and a detailed description has been published elsewhere(11). Birth 99 
weight was obtained without a nappy using a calibrated electronic scale. Length was measured on a 100 
standardized plastic length board constructed for use in the HAPO Study. Head circumference was 101 
measured across the occipital fontanel (standard plastic measuring tape). Skin fold thickness was 102 
measured with skin fold calipers (Harpenden, Baty, U.K.). Triceps, subscapular, and flank skin fold 103 
thicknesses were measured twice, and if results differed by more than 0.5 mm, a third measurement 104 
was made.  105 
Overall, 23316 blinded participants successfully completed the study. Of the participating 1677 106 
women from the Belfast centre, 37 women were removed from the study due to glucose intolerance 107 
and being unblinded [n=1640 (98%)]. A further 28 women were of non-white European ethnicity 108 
and were removed from the analysis due to the relationship between GDM and ethnicity (14) 109 
[n=1612 (96%)]. Of these 1612 women, six had antepartum fetal deaths and two had neonatal 110 
deaths. Serological samples for the measurement of vitamin D were available for 1585 women.  111 
Laboratory analysis 112 
25OHD2/D3 and 3-epi-25hydroxyvitamin D2/D3 (3-epi-25OHD2/ D3) in serum samples were 113 
measured using a liquid chromatography tandem-mass spectrometry (LC-MS/MS) method 114 
[Waters® Xevo TQ-S® & ACQUITY UPLC (Waters Corporation, UK)].  115 
For 25OHD2/D3, calibration was achieved using commercially available 25OHD2/D3 bi-level (level 116 
I and level II) serum controls (Chromsystems, Germany) diluted in horse serum (Sigma-Aldrich Co 117 
Ltd., UK). Low, medium and high quality control (QC) samples were prepared by diluting 118 
25OHD2/D3 level I and II serum controls in horse serum. For 3-epi-25OHD2/D3, calibration was 119 
achieved using commercially available 3-epi-25OHD2/D3 (Sigma-Aldrich Co Ltd., UK) diluted in 120 
methanol (Fisher Scientific; UK) to make a stock solution of 270 nmol/L. Extra low, low, medium 121 
and high QC samples were prepared by diluting 3-epi-25OHD2/D3 stock solution in horse serum 122 
(Invitrogen Life Technologies, UK). The final concentrations of the extra low, low, medium and 123 
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high QC samples were 8.438, 16.875, 67.5 and 135 nmol/L, respectively, for both 3-epi-25OHD2 124 
and 3-epi-25OHD3.  125 
A liquid-liquid extraction method was used to extract serum samples for 25OHD2/D3 and 3-epi-126 
25OHD2/D3. Hexadeuterated 25OHD3 (d6-25OHD3; internal standard; Synthetica AS, Norway) 127 
and trideuterated 3-epi-25OHD3 (d3-3-epi-25OHD3; internal standard, Sigma-Aldrich Co Ltd., UK) 128 
were added to calibrator, quality control and participant’s serum samples to correct for variability 129 
during sample preparation.  130 
The extracted sample (20 µL) was injected onto an Agilent Zorbax SB-CN column (2.1 x 50 mm; 131 
1.8 µm particle size). A Waters Xevo TQ-S Tandem Quadrupole Mass Spectrometer was used to 132 
quantify the amount of 25OHD and 3-epi-25OHD in samples. Instrument analysis time was 17.5 133 
minutes per sample. 134 
The inter-assay coefficients of variation (CVs) of the method for 25OHD2 and 25OHD3 were 4.4% 135 
and 3.4% at concentration 16.1 nmol/L, respectively, while the intra-assay CVs were 2.7 and 2.3%, 136 
respectively. The interassay CVs of the method for 3-epi-25OHD2 and 3-epi-25OHD3 were 2.3 and 137 
2.6% at concentration 8.4 nmol/L, respectively, while the intra-assay CV were 5.5 and 4.5%, 138 
respectively. The quality and accuracy of serum 25OHD analysis using the LC-MS/MS method in 139 
our laboratory was monitored on an ongoing basis by participation in the Vitamin D External 140 
Quality Assessment Scheme (Charing Cross Hospital); however, this scheme was for total serum 141 
25OHD and does not take into consideration 3-epi-25OHD. Commercially available quality control 142 
samples (Chromsysytems, Germany) were extracted and analyzed in parallel to the serum samples, 143 
and were strategically placed close to the beginning, middle and end of the analysis on the LC–144 
MS/MS instrument, in addition, a number of patient samples were also routinely re-analyzed on a 145 
daily basis to ensure accuracy and precision of the method. 146 
The measurement of all maternal and cord glucose samples were done at the HAPO Central 147 
Laboratory (Belfast, Northern Ireland, U.K.). Aliquots of maternal fasting, 1-hour and 2-hour 148 
OGTT specimens and serum cord were analyzed for glucose using a chemical analyser (Vitros 750; 149 
OrthoClinical Diagnostics, Rochester, NY) by an oxidase/peroxidase method. Cord c-peptide was 150 
measured only in non-haemolysed samples by a two-way immunometric assay on  an Autodelfia 151 
instrument (Waltham, MA).  152 
Statistical analysis 153 
Statistical analysis in the Belfast HAPO cohort was carried out using SPSS version 21 (IBM Corp, 154 
Armonk, NY, USA). Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and 155 
Homeostatic Model Assessment-Beta (HOMA-beta) were calculated using the HOMA2 calculator 156 
(15).  157 
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Birth weight, birth height and head circumference were converted to standard deviation scores 158 
(SDS) using the 1990 British Growth Standard which takes into consideration the offspring gender 159 
and gestational age (16). Neonates born before 36 weeks gestation were removed for analysis with fat 160 
mass, as the equation does not apply to those neonates born <36 weeks gestation. Season of 161 
maternal OGTT was defined as winter/spring (November, December, January, February, March, 162 
April) or summer/fall (May, June, July, August, September, October) for regression analysis. Total 163 
25OHD was comprised of 25OHD2 and 25OHD3, of which 25OHD3 is the main constituent. Total 164 
25OHD was split into quintiles for certain analysis (≤25 nmol/L, 25.01 to 49.9 nmol/L, 50 to 74.9 165 
nmol/L, 75-99.9 nmol/L and ≥100 nmol/L).  166 
Variables were examined for a normal distribution using normality plots and serum 25OHD, cord 167 
HOMA-IR, and cord HOMA-beta were logarithmically transformed to the base 2 because their 168 
distributions were positively skewed. Pearson’s correlation coefficient was used to assess the 169 
association between total 25OHD concentrations and continuous variables. Independent samples t-170 
tests and one-way analysis of variance (ANOVA) were used to compare total 25OHD 171 
concentrations between groups defined by variables with two and three or more categories, 172 
respectively.  173 
Multiple linear regressions were used to determine the independent association of total 25OHD with 174 
a number of neonatal anthropometric measurements, cord HOMA-IR and cord HOMA-beta. 175 
Analyses were adjusted for a number of variables: season of sampling, maternal age at OGTT, body 176 
mass index (BMI) at OGTT, smoker during pregnancy, alcohol user during pregnancy, family 177 
history of diabetes, gestational age at delivery, gender of neonate, parity, systolic blood pressure at 178 
OGTT, maternal height, fasting plasma glucose (excluded in cord HOMA-IR/beta analysis), and 179 
maternal education.  180 
Results are presented as means (geometric means if the variable was log transformed) and 95% 181 
confidence intervals (CIs). Regression coefficients were back transformed if the dependent variable 182 
was logged. A p value less than or equal to 0.05 was considered statistically significant. 183 
Ethics- Written informed consent was obtained from all study participants. Ethical approval was 184 
obtained from the Northern Ireland Regional Ethics Committee and the research adhered to the 185 
tenets of the Declaration of Helsinki.  186 
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Results 188 
Neonatal birth weights were obtained in 1605 neonates, and other neonatal anthropometric 189 
measurements were obtained in smaller numbers (1507-1601). Cord measurements of insulin 190 
resistance and beta cell function were available in 1150 neonates born to Belfast HAPO mothers. 191 
Descriptive statistics for the mother at 28 weeks gestation and the neonate are shown in Table 1. 192 
The mean ± SD age and body mass index (BMI) at the OGTT of participants in the HAPO study at 193 
the Belfast centre were 29.7 ±5.5 years, and 28.3 ±4.6 kg/m2, respectively. Women had blood 194 
samples taken on average at 29 weeks gestation. The prevalence of cigarette smoking and alcohol 195 
use during pregnancy was relatively high (24.1% and 26.9%, respectively). The mean ± SD 196 
maternal 25OHD concentration was 46.3 ±30.3 nmol/L. No 3-epi-25OHD2 was present in 197 
participant samples. 3-epi-25OHD3 concentrations were low (2.9 ±1.9 nmol/L) and present in 95% 198 
of all participants sampled. Dietary vitamin D as estimated from the FFQ was low (3.3 ±2.5 199 
µg/day), and below the recommended nutrient intake (RNI) of 10 µg/day for pregnant women in the 200 
UK(17), however, it should be again noted, that the FFQ did not quantify vitamin D from nutritional 201 
supplements and fortified foods. The prevalence of vitamin D deficiency was high, with 26.7% of 202 
women having 25OHD concentrations less than 25 nmol/L. Neonates at the Belfast HAPO Centre 203 
were born at an average of 40 weeks gestation. The average birth weight was 3,402 ± 517 g and the 204 
average birth weight SDS was -0.1 ± 1.0. The average birth length was 50.8 ± 2.5 cm and birth 205 
length SDS was 0.2 ± 1.1.  206 
Circulating concentrations of maternal 25OHD were not significantly correlated with maternal age 207 
or maternal BMI, however, 25OHD was significantly and positively correlated with years of 208 
education (p≤0.001) (data not shown). Serum 25OHD was significantly lower in those women who 209 
smoked during pregnancy (p≤0.001). There were no significant differences in 25OHD 210 
concentrations between alcohol use and non-alcohol use during pregnancy. There was evidence of 211 
seasonal variation in 25OHD concentrations. Maternal 25OHD concentrations were lower in the 212 
winter/spring (29.3 nmol/L) compared to summer/fall (47.6 nmol/L) (data not shown).   213 
Total 25OHD was split into quintiles (≤25 nmol/L, 25.01-49.99 nmol/L, 50-74.99 nmol/L, 75-99.99 214 
nmol/L and ≥100 nmol/L) and neonatal anthropometric outcomes were compared. There were no 215 
significant differences between the quintiles of total 25OHD and birth weight, birth length, neonatal 216 
fat mass, neonatal subscapular skinfold, neonatal flank skinfold thickness and neonatal triceps’ 217 
skinfold thickness (data not shown). In addition, no significant differences were observed between 218 
quintiles of total 25OHD and markers of neonatal glycaemia (data not shown).   219 
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Table 2 shows the associations between maternal 25OHD at 28 weeks gestation and neonatal 220 
anthropometric measurements adjusted for confounders. The regression analysis found that the 221 
doubling of maternal 25OHD gave rise to a birth weight higher by 0.05 and birth length SDS higher 222 
by 0.07 (both, p=0.03). No associations were found for neonatal measures of skinfold thickness 223 
with maternal 25OHD (Table 2).  224 
No significant associations were observed between maternal 25OHD concentrations at 28 weeks’ 225 
gestation and cord HOMA-IR and cord HOMA-beta in both the unadjusted analysis and adjusted 226 
analysis (Table 3).  227 
  228 
 10 
Discussion 229 
Maternal vitamin D deficiency was common in participants in the Belfast HAPO study. After 230 
adjustment for confounding variables, maternal serum 25OHD was associated only with neonatal 231 
birth weight SDS and birth length SDS. However, the contribution of maternal 25OHD to these 232 
neonatal anthropometric outcomes appears to be limited. No associations were observed with 233 
maternal 25OHD and markers of neonatal beta-cell function and insulin resistance.  234 
There is conflicting evidence regarding the relationship between vitamin D and neonatal and 235 
maternal outcomes. A number of studies have found associations of maternal vitamin D status with 236 
a number of neonatal outcomes, including birth weight (18), pre-term birth (4), asthma and allergies 237 
(19). The conflicting results are most likely due to low numbers of participants in the studies, and 238 
failure to control for relevant confounding variables. Well-designed longitudinal observational 239 
studies are required to investigate thoroughly maternal-neonatal associations with vitamin D. These 240 
might in turn point to the need for large-scale vitamin D intervention trials to investigate the 241 
association of 25OHD with maternal and neonatal outcomes. In the current study, maternal 25OHD 242 
was significantly associated with birth weight SDS in adjusted analysis. Further, there was a lack of 243 
association between maternal 25OHD with measures of neonatal adiposity. One small study 244 
reported greater neonatal fat mass with higher cord 25OHD concentrations (20) and that cord 25OHD 245 
was directly related to maternal 25OHD concentrations (21). While we did not measure cord 25OHD, 246 
our data pertain to a much larger cohort of mother-neonate pairs, and our results have been adjusted 247 
for a considerable number of confounding variables. The lack of significant associations in the 248 
present study between maternal 25OHD and neonatal adiposity is also concordant with the results 249 
from a sub sample of a North American HAPO cohort which also found no significant association 250 
between cord 25OHD and neonatal adiposity (21). 251 
Previous studies which have examined the association between maternal vitamin D and birth weight 252 
have reached conflicting conclusions. In an observational study, Gernard and colleagues assessed 253 
the 25OHD concentrations of 2146 pregnant women at 26 weeks gestation and reported mean 254 
maternal 25OHD concentrations of 51.3 nmol/L similar to findings in the current study (46.3 255 
nmol/L). The authors observed a non-linear relationship between 25OHD concentrations and birth 256 
weight. When adjusted for several confounders (trimester at maternal blood draw, maternal race 257 
(white/other), pre-pregnancy BMI, height, smoking, season, and study site) maternal 25OHD 258 
concentrations higher by 1 nmol/L were associated with mean neonatal birth weight higher by 3.6g 259 
(6). A prospective cohort study preformed in a number of cities in Spain among 2,382 pregnant 260 
women during the early second trimester reported a median circulating 25OHD level of 73.4 261 
nmol/L. No association was found between maternal 25OHD concentrations and neonatal birth 262 
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weight in either the unadjusted or adjusted analysis. In addition, maternal 25OHD was not 263 
associated with low birth weight (<2,500g) (22). It is possible that the association of vitamin D with 264 
low birth weight is only observed in vitamin D deficient mothers. A prospective study by Chen and 265 
colleagues in 3,658 pregnant women reported a significant positive correlation between maternal 266 
25OHD and birth weight (r=0.477; p<0.001), with evidence of a threshold of 100 nmol/L for 267 
maternal 25OHD concentrations below which vitamin D was an important predictor of neonatal 268 
birth weight but above which there was no association (23). The evidence, therefore, regarding the 269 
relationship between vitamin D and birth weight is inconclusive. There are data  which suggest an 270 
association between maternal glucose and fatty acid metabolism and therefore the transfer of energy 271 
to the foetus, and consequently increase neonatal birth weight(6). The relationship with vitamin D 272 
and birth weight could also be simply explained by a healthy maternal diet, which in turn increases 273 
25OHD concentrations and gives rise to an increased birth weight in the neonate.  274 
A significant association was observed in the current study between maternal 25OHD 275 
concentrations and birth length SDS. This is in line with a large mother-neonate study in the US 276 
(n=2473)(24). In this latter study, maternal 25OHD at 26 weeks gestation was 58.9 nmol/L, and a 277 
significant positive association was observed between 25OHD and birth length Z-score in adjusted 278 
analysis. The authors also observed that this association was sustained from birth to 12 months (24), 279 
which would suggest that skeletal growth deficits in infants with low maternal 25OHD may be 280 
difficult to recover. This is concordant with a previous study which suggested maternal vitamin D 281 
status is associated with reduced bone mass accrual during childhood up to 9 years of age (25). The 282 
effect of maternal vitamin D on birth length, and perhaps bone mass, could be linked to the 283 
maternal-foetal transfer of calcium during pregnancy. Javaid and colleagues observed that 284 
umbilical-venous concentrations of calcium were significantly associated with bone mass accrual in 285 
offspring (25). The main role of vitamin D in pregnancy is to escalate calcium absorption and 286 
placental calcium transport (26). It is possible that vitamin D deficiency may reduce the capacity of 287 
maternal transfer of calcium to the foetus and therefore decrease bone mass, and bone length.  288 
25OHD concentrations above the threshold of deficiency have been associated with improved beta 289 
cell function in various population groups (8),(9), however, this was not observed in the current study. 290 
Vitamin D actions are mediated by vitamin D receptors (VDRs), which undergo several processes 291 
to activate metabolic regulatory factors, including insulin. VDRs are present in beta cells, which 292 
suggest vitamin D may have a direct involvement in regulating beta cell function (27). Information 293 
on the impact of maternal vitamin D deficiency on the incidence of type 1 diabetes in the offspring 294 
is limited. A meta-analysis on the association between maternal vitamin D intake and the risk of 295 
type 1 diabetes was conducted by Dong and colleagues. Three studies were included in the analysis 296 
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and the pooled odds-ratio (OR) was 0.95 (95% CI, 0.66–1.36) indicating no association between 297 
maternal intake of vitamin D and risk of type 1 diabetes in the offspring (28). Due to limited 298 
literature on the impact of maternal vitamin D concentration on neonatal beta cell function, it is 299 
difficult to assess if further investigation is warranted regarding maternal vitamin D and the risk of 300 
diabetes in the offspring.  301 
The strengths of this study include the large number of participants, the rigorous nature of the 302 
methodology, the detailed neonatal endpoints and the methodology for vitamin D measurement 303 
during pregnancy. In addition, exploration of the association between maternal vitamin D and 304 
neonatal outcomes was controlled for relevant confounding variables. The limitations include the 305 
observational nature of the study and the use of HOMA equations to assess beta cell function and 306 
insulin resistance. Information on cord HOMA-beta and HOMA-IR was only available for 75% of 307 
the total study population which reduced the sample size for analysis of cord HOMA-beta and 308 
HOMA-IR. In addition, we did not measure 25OHD in cord blood which would have provided 309 
further information on the relation of maternal 25OHD to neonatal adiposity.  310 
In future studies, we plan to examine the associations of maternal 25OHD on offspring bone mass 311 
and bone length in childhood years. In summary, the present study has shown a positive association 312 
between maternal 25OHD and birth weight SDS and birth length SDS controlled for confounding 313 
variables, however, the contribution of maternal 25OHD in regression models appears to be limited. 314 
No other significant associations were found for other measures of neonatal anthropometry. In 315 
general, it would seem wise to encourage pregnant women to maintain 25OHD concentrations ≥25 316 
nmol/L for skeletal health and to prevent the neonate being vitamin D deficient.  317 
 318 
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Table 1 Neonatal anthropometric outcomes and biochemical insulin indices in neonates born to 
Belfast HAPO mothers 
 
25OHD, 25-hydroxy vitamin D HAPO, Hyperglycemia and Adverse Pregnancy Outcome Study HOMA-beta, 
Homeostasis model assessment-of beta cell function HOMA-IR, Homeostasis model assessment-of insulin resistance 
SDS, Standard deviation score. 
Variable N (%) Range Mean  Standard 
deviation 
Mother at OGTT     
Age (years) 1612 18.1 to 43.3 29.7 5.5 
Weight (kg) 1611 46.9 to 137.3 75.0 12.8 
Height (cm) 1612 139.8 to 183.1 162.9 6.3 
BMI (kg/m2) 1611 18.1 to 50.3 28.3 4.6 
Gestational age (weeks) 1612 23.9 to 33.1 29.0 1.2 
Education (years) 1601 10 to 27 15 3 
Ethnicity 
Caucasian 
 
1612/1612 
(100%) 
- -  
Smoker during pregnancy 388/1612 
(24.1%) 
- -  
Alcohol use during 
pregnancy  
434/1612 
(26.9%) 
- -  
Fasting plasma glucose 
(mmol/L) 
1612 3.6 to 6.2 4.6 0.3 
1-hour glucose (mmol/L) 1611 2.8 to 10.2 7.4 1.7 
2-hour glucose (mmol/L) 1612 2.4 to 10.2 6.0 1.2 
Total 25OHD (nmol/L)b 1585 3.1 to 266.1 38.6 24.1, 60.7 
3-epi-25OHD3 (nmol/L) 1512 2.7 to 20.0 2.9 1.9 
Dietary vitamin D 
(μg/day) 
1568 0.0 to 29.8 3.3 2.5 
Vitamin D deficient (≤25 
nmol/L) 
423/1585 
(26.7%) 
- -  
Neonatal measurements     
Birth weight (g) 1605 1070 to 5000 3402 517 
Birth weight SDS 1605 -3.1 to 3.5 -0.1 1.0 
Birth length (cm) 1593 41.3 to 60.5 50.8 2.5 
Birth length SDS 1593 -4.3 to 5.2 0.1 1.1 
Head circumference (cm) 1601 25.6 to 39.7 35.0 1.5 
Head circumference SDS 1601 -3.4 to 3.6 0.2 1.0 
Fat mass (g)a 1490 1.9 to 1070.9 420.3 168.6 
Subscapular skinfold 
thickness (cm) 
1510 2.1 to 8.1 4.4 1.0 
Flank skinfold thickness 
(cm) 
1510 1.8 to 8.1 4.0 0.9 
Triceps skinfold thickness 
(cm) 
1507 2.0 to 8.1 4.1 0.9 
Cord glucose (mmol/L) 1352 2.1 to 12.7 4.5 1.1 
Cord HOMA-betab  1150 17.1 to 412.7 101.2 69.0, 142.2 
Cord HOMA-IRb 1150 0.4 to 3.9 0.7  0.5, 1.0 
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a- Neonates born <36 weeks gestation were removed from analysis. 
b- Values expressed as median and interquartile range 
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Table 2 Unadjusted and adjusted associations of maternal 25OHD at 28 weeks’ gestation with neonatal anthropometric measurements 
 
 
 
 
 
 
 
 
25OHD, 25-hydroxyvitamin D CI, confidence intervals SDS, Standard deviation score 
a- Regression coefficients represent the additive effect on the dependent variable associated with a doubling in maternal serum 25OHD level (due to 25OHD being logged to 
the base 2). 
b- Adjusted for season of sampling, maternal age at OGTT, maternal BMI at OGTT, smoker during pregnancy, alcohol use during pregnancy, family history of diabetes, 
gestational age at delivery, gender of neonate, parity, systolic blood pressure at OGTT, maternal height, fasting plasma glucose and maternal education 
c- Neonates born <36 weeks gestation were excluded from analysis. 
  
  Unadjusted Adjusted b 
Dependent variables n Coefficient a 
(95% CI) 
p-value R2 Coefficient a 
(95% CI) 
p-value R2 
Birth weight SDS 1555 0.08 (0.03 to 0.13) 0.002 0.01 0.05 (0.00 to 0.10) 0.03 0.21 
Birth length SDS 1543 0.08 (0.02 to 0.14) 0.007 0.01 0.07 (0.01 to 0.13) 0.03 0.12 
Head circumference SDS 1551 0.06 (0.01 to 0.12) 0.02 0.00 0.05 (-0.00 to 0.11) 0.08 0.11 
Fat mass (g) c 1442 11.91 (2.90 to 20.92) 0.01 0.01 7.95 (-0.80 to 16.70) 0.08 0.24 
Subscapular skinfold (cm) 1462 0.06 (0.00 to 0.11) 0.03 0.00 0.04 (-0.01 to 0.10) 0.11 0.13 
Flank skinfold (cm) 1462 0.06 (0.01 to 0.11) 0.02 0.00 0.03 (-0.02 to 0.08) 0.25 0.13 
Triceps skinfold (cm) 1459 0.06 (0.01 to 0.11) 0.01 0.00 0.04 (-0.01 to 0.09) 0.13 0.13 
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Table 3-Summary table of the relationship of maternal 25OHD at 28 weeks’ gestation to markers of neonatal glycaemia 
 
 
 
 
 
25OHD, 25-hydroxyvitamin D CI, confidence intervals HOMA-beta, homeostatic model of assessment-beta HOMA-IR, homeostatic model of assessment-insulin resistance. 
a-Regression coefficients have been antilogged to represent the multiplicative effect on the dependent variable associated with a doubling in maternal serum 25OHD level 
(due to 25OHD being logged to the base 2).  
b- Adjusted for season of sampling, maternal age at OGTT, maternal BMI at OGTT, smoker during pregnancy, alcohol use during pregnancy, family history of diabetes, 
gestational age at delivery, gender of neonate, parity, systolic blood pressure at OGTT, maternal height, and maternal education 
 
  Unadjusted Adjustedb 
Dependent variables n Coefficient(95% CI) p-value R2 Coefficient(95% CI) p-value R2 
Cord glucose 
(mmol/L) 
1314 -0.02 (-0.08 to 0.04) 0.55 0.00 -0.05 (-0.11 to 0.02) 0.16 0.09 
Cord HOMA-Beta a 1105 1.03 (1.00 to 1.06) 0.10 0.00 1.03(1.00 to 1.06) 0.08 0.10 
Cord HOMA-IR a 1105 1.03(1.00 to 1.06) 0.05 0.00 1.01(0.98 to 1.04) 0.58 0.06 
